세계의 하이드록시클로로퀸 시장 규모 분석 : 적응 질환별, 유통 채널별, 지역별 예측(2025-2035년)

Global Hydroxychloroquine Market is valued at approximately USD 1.12 billion in 2024 and is expected to expand at a robust CAGR of 4.70% throughout the forecast period from 2025 to 2035. Hydroxychloroquine, a time-tested antimalarial and immunomodulatory drug, has garnered renewed attention in recent years due to its off-label applications, particularly during global health emergencies. This compound plays a critical role in managing chronic autoimmune diseases such as rheumatoid arthritis and lupus erythematosus. Additionally, its cost-effectiveness and broad pharmacological profile have fueled its prescription across a diverse set of healthcare systems. The market's growth is largely underpinned by increasing prevalence of vector-borne diseases and autoimmune conditions, alongside rising awareness and accessibility of disease-modifying treatments in both developing and developed nations.

The resurgence of hydroxychloroquine during the COVID-19 pandemic has contributed to a temporary spike in global demand, accelerating its production and distribution infrastructure. While regulatory agencies remain cautious about its antiviral utility, this event showcased hydroxychloroquine's adaptability in emergency preparedness pipelines. Moreover, persistent cases of malaria in parts of Africa, Asia, and Latin America continue to secure a baseline demand. Pharmaceutical players are investing in extended-release formulations and combination therapies to improve patient compliance and broaden the drug's therapeutic spectrum. However, the market still grapples with regulatory scrutiny surrounding its side effects, as prolonged use may lead to serious ophthalmic and cardiovascular complications-limiting its unrestricted adoption in some regions.

From a regional perspective, North America represents a substantial share in the hydroxychloroquine market, fueled by the high incidence of autoimmune diseases, widespread insurance coverage, and strong R&D backing. Europe follows closely, buoyed by structured clinical guidelines and high treatment adherence rates. Meanwhile, the Asia Pacific region is expected to witness the fastest growth rate during the forecast period, owing to a high malaria burden and increasing government efforts to enhance healthcare infrastructure in countries like India and Indonesia. Latin America and the Middle East & Africa also contribute significantly due to ongoing malaria control programs and growing awareness of rheumatologic treatments.

Major market player included in this report are:

• Zydus Lifesciences Ltd.
• Sanofi S.A.
• Mylan N.V.
• Novartis AG
• Ipca Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Lupin Limited
• Apotex Inc.
• Sun Pharmaceutical Industries Ltd.
• Sandoz Inc.
• Cadila Healthcare
• Bayer AG
• Dr. Reddy's Laboratories Ltd.

Global Hydroxychloroquine Market Report Scope:

• Historical Data - 2023, 2024
• Base Year for Estimation - 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Disease Indication:

• Malaria
• COVID-19
• Rheumatoid Arthritis
• Others

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Stores

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Hydroxychloroquine Market Report Scope & Methodology

• 1.1. Research Objective
• 1.2. Research Methodology
  • 1.2.1. Forecast Model
  • 1.2.2. Desk Research
  • 1.2.3. Top-Down and Bottom-Up Approach
• 1.3. Research Attributes
• 1.4. Scope of the Study
  • 1.4.1. Market Definition
  • 1.4.2. Market Segmentation
• 1.5. Research Assumption
  • 1.5.1. Inclusion & Exclusion
  • 1.5.2. Limitations
  • 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

• 2.1. CEO/CXO Standpoint
• 2.2. Strategic Insights
• 2.3. ESG Analysis
• 2.4. Key Findings

Chapter 3. Global Hydroxychloroquine Market Forces Analysis

• 3.1. Market Forces Shaping the Global Hydroxychloroquine Market 2024-2035
• 3.2. Drivers
  • 3.2.1. Persistent Malaria Burden and Autoimmune Disease Prevalence
  • 3.2.2. Off-Label Demand Surge During Health Crises (e.g., COVID-19)
• 3.3. Restraints
  • 3.3.1. Stringent Regulatory Scrutiny over Safety and Side Effects
  • 3.3.2. Competitive Pressure from Novel Therapeutics
• 3.4. Opportunities
  • 3.4.1. Expanded Access through E-Pharmacy and Telehealth Channels
  • 3.4.2. Development of Extended-Release and Combination Formulations

Chapter 4. Global Hydroxychloroquine Industry Analysis

• 4.1. Porter's Five Forces Model
  • 4.1.1. Bargaining Power of Buyer
  • 4.1.2. Bargaining Power of Supplier
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's Five Forces Forecast Model 2024-2035
• 4.3. PESTEL Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top Investment Opportunities
• 4.5. Top Winning Strategies 2025
• 4.6. Market Share Analysis 2024-2025
• 4.7. Global Pricing Analysis and Trends 2025
• 4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Hydroxychloroquine Market Size & Forecasts by Disease Indication 2025-2035

• 5.1. Market Overview
• 5.2. Global Hydroxychloroquine Market Performance - Potential Analysis 2025
• 5.3. Malaria
  • 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 5.3.2. Market Size Analysis, by Region, 2025-2035
• 5.4. COVID-19
  • 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 5.4.2. Market Size Analysis, by Region, 2025-2035
• 5.5. Rheumatoid Arthritis
  • 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 5.5.2. Market Size Analysis, by Region, 2025-2035
• 5.6. Others
  • 5.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 5.6.2. Market Size Analysis, by Region, 2025-2035

Chapter 6. Global Hydroxychloroquine Market Size & Forecasts by Distribution Channel 2025-2035

• 6.1. Market Overview
• 6.2. Global Hydroxychloroquine Market Performance - Potential Analysis 2025
• 6.3. Hospital Pharmacy
  • 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 6.3.2. Market Size Analysis, by Region, 2025-2035
• 6.4. Retail Pharmacy
  • 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 6.4.2. Market Size Analysis, by Region, 2025-2035
• 6.5. Online Stores
  • 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 6.5.2. Market Size Analysis, by Region, 2025-2035

Chapter 7. Global Hydroxychloroquine Market Size & Forecasts by Region 2025-2035

• 7.1. Hydroxychloroquine Market, Regional Market Snapshot
• 7.2. Top Leading & Emerging Countries
• 7.3. North America
  • 7.3.1. U.S. - Estimates & Forecasts, 2024-2035
  • 7.3.2. Canada - Estimates & Forecasts, 2024-2035
• 7.4. Europe
  • 7.4.1. UK - Estimates & Forecasts, 2024-2035
  • 7.4.2. Germany - Estimates & Forecasts, 2024-2035
  • 7.4.3. France - Estimates & Forecasts, 2024-2035
  • 7.4.4. Spain - Estimates & Forecasts, 2024-2035
  • 7.4.5. Italy - Estimates & Forecasts, 2024-2035
  • 7.4.6. Rest of Europe - Estimates & Forecasts, 2024-2035
• 7.5. Asia Pacific
  • 7.5.1. China - Estimates & Forecasts, 2024-2035
  • 7.5.2. India - Estimates & Forecasts, 2024-2035
  • 7.5.3. Japan - Estimates & Forecasts, 2024-2035
  • 7.5.4. Australia - Estimates & Forecasts, 2024-2035
  • 7.5.5. South Korea - Estimates & Forecasts, 2024-2035
  • 7.5.6. Rest of Asia Pacific - Estimates & Forecasts, 2024-2035
• 7.6. Latin America
  • 7.6.1. Brazil - Estimates & Forecasts, 2024-2035
  • 7.6.2. Mexico - Estimates & Forecasts, 2024-2035
• 7.7. Middle East & Africa
  • 7.7.1. UAE - Estimates & Forecasts, 2024-2035
  • 7.7.2. Saudi Arabia - Estimates & Forecasts, 2024-2035
  • 7.7.3. South Africa - Estimates & Forecasts, 2024-2035
  • 7.7.4. Rest of Middle East & Africa - Estimates & Forecasts, 2024-2035

Chapter 8. Competitive Intelligence

• 8.1. Top Market Strategies
• 8.2. Zydus Lifesciences Ltd.
  • 8.2.1. Company Overview
  • 8.2.2. Key Executives
  • 8.2.3. Company Snapshot
  • 8.2.4. Financial Performance (Subject to Data Availability)
  • 8.2.5. Product/Services Portfolio
  • 8.2.6. Recent Developments
  • 8.2.7. Market Strategies
  • 8.2.8. SWOT Analysis
• 8.3. Sanofi S.A.
• 8.4. Mylan N.V.
• 8.5. Novartis AG
• 8.6. Ipca Laboratories Ltd.
• 8.7. Hikma Pharmaceuticals PLC
• 8.8. Teva Pharmaceutical Industries Ltd.
• 8.9. Torrent Pharmaceuticals Ltd.
• 8.10. Lupin Limited
• 8.11. Apotex Inc.
• 8.12. Sun Pharmaceutical Industries Ltd.
• 8.13. Sandoz Inc.
• 8.14. Cadila Healthcare
• 8.15. Bayer AG
• 8.16. Dr. Reddy's Laboratories Ltd.